Verrica announces positive results for molluscum contagiosum treatment
Category: #health  By Mateen Dalal  Date: 2019-03-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Verrica announces positive results for molluscum contagiosum treatment

The treatment would help to address unmet medical needs against serious skin lesions

Reports suggest that the lead candidate of Verrica Pharmaceuticals, a drug-device combination for dermatology indication, has achieved primary endpoints in two of the Phase 3 trials while testing in molluscum contagiosum, a skin infection.

Apparently, this treatment beat out placebo in reducing the number of lesions and completely clearing treatable lesions in both studies. The Pennsylvania-based firm is planning to file a New Drug Application (NDA) for the asset, termed as VP-102, in second half of year 2019.

Lead investigator for the VP-102 phase 3 molluscum program and Chief of adolescent and pediatric dermatology at Rady Children’s Hospital-San Diego, Lawrence Eichenfield, M.D., mentioned that the current methods of treatment have huge limitations, which include unproven efficacy, scarring, pain. Also, many are not suitable for use in children, he stated.

Eichenfield further said that VP-102 addresses unmet medical needs for treating serious skin lesions that could spread very quickly among children and within families, if it is left untreated, could lead towards secondary infections, skin inflammation, anxiety and social stigma.

The data, which was presented at the American Academy of Dermatology’s annual meeting, has allegedly followed topline results announced in January. Both the trails, known as CAMP-1 and CAMP-2, had been randomized, placebo-controlled double-blind trials which pitted VP-102 against placebo in 528 patients suffering from molluscum. In a single-use applicator, VP-102 is a topical treatment which contains a solution of 0.7 percent cantharidin.

Further from the reports, for up to a total of 12 weeks, patients were treated once in every three weeks. Studies revealed that 26 percent of patients treated in CAMP-1 and 54 percent of patients treated in CAMP-2 had finished clearance of all treatable molluscum lesions.

Purportedly, the placebo group numbers were 18 percent and 13 percent, respectively. In mean reduction of the number of lesions, VP-102 performed similarly, 69 percent and 83 percent reduction in CAMP-1 and CAMP-2. Placebo patients in CAMP-2 had a 19 percent reduction, while those in CAMP-1 had a 20% increase.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...